MorphoSys AG

MOR

DE0006632003

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 09:45:54 2024-04-24 am EDT			5-day change	1st Jan Change
67.72 ^EUR	-0.04%		+0.07%	+99.26%

Apr. 11	Health Care Slips on Risk Bias -- Health Care Roundup	DJ
Apr. 11	Trending : Novartis Begins Tender Offer for MorphoSys Shares	DJ

MORPHOSYS : Goldman Sachs reiterates its Neutral rating

November 18, 2020 at 09:45 am EST

Analyst Graig Suvannavejh from Goldman Sachs research gives the stock a Neutral rating. The target price is unchanged at EUR 110.

Latest news about MorphoSys AG

Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
Novartis: MorphoSys Board recommends tender offer	Apr. 11	CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins	Apr. 11	MT
Morphosys management bodies recommend acceptance of Novartis takeover bid	Apr. 11	DP
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
Novartis Launches Tender Offer for Germany's MorphoSys	Apr. 11	MT
Novartis initiates tender offer for MorphoSys	Apr. 11	CF
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
MorphoSys Gets US Antitrust Approval for Proposed Acquisition by Novartis	Mar. 22	MT
Novartis' EUR2.7 Billion Purchase of MorphoSys Secures US Antitrust Clearance	Mar. 22	MT
INDEX-MONITOR: Morphosys and Bilfinger in the MDax as of today - Dax unchanged	Mar. 18	DP
MorphoSys AG(XTRA:MOR) added to Germany MDAX Index (Performance)	Mar. 17	CI
MorphoSys AG(XTRA:MOR) dropped from Germany SDAX (Total Return) Index	Mar. 14	CI
Morphosys sees no obstacle on its way under the Novartis umbrella	Mar. 14	DP
Transcript : MorphoSys AG, 2023 Earnings Call, Mar 14, 2024	Mar. 14
MorphoSys Q4 EPS, Revenue Decrease	Mar. 13	MT
Morphosys with higher loss - takeover process by Novartis going according to plan	Mar. 13	DP
MorphoSys AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Earnings Flash (MOR) MORPHOSYS AG Posts Q4 Revenue EUR59M	Mar. 13	MT
MorphoSys AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
German Regulator Clears Novartis' Takeover of MorphoSys	Mar. 12	MT
INDEX-MONITOR: Morphosys and Bilfinger move up to MDax - Dax unchanged	Mar. 06	DP
Deutsche Börse's Stoxx to Make Changes to DAX Indices	Mar. 06	MT
INDEX-MONITOR: Morphosys and Vitesco likely to swap places in March	Mar. 04	DP

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - Q1 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for MorphoSys AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

67.75 EUR

Average target price

58.71 EUR

Spread / Average Target

-13.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+99.26%	2.73B
IQVIA HOLDINGS INC.	+4.78%	43.43B
LONZA GROUP AG	+48.94%	41.69B
MODERNA, INC.	+8.63%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+10.35%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.44%	18.47B
MEDPACE HOLDINGS, INC.	+36.90%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.88%	12.33B
UNITED THERAPEUTICS CORPORATION	+6.48%	11.03B

Other Biotechnology & Medical Research

MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

MORPHOSYS : Goldman Sachs reiterates its Neutral rating

Latest news about MorphoSys AG

Chart MorphoSys AG

Company Profile

Income Statement Evolution

Ratings for MorphoSys AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research